Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Issue 2 (November 2015)

• Record Type: Journal Article
• Authors: Miroddi, Marco; Sterrantino, Carmelo; Simonelli, Ilaria; Ciminata, Giorgio; Phillips, Robert S.; Calapai, Gioacchino
• Is Part Of: Critical reviews in oncology/hematology. Volume 96:Issue 2(2015)
• Page Start: 355
• Page End: 371
• Publication Date: 2015-11
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2015.06.004
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">We reviewed 18 clinical trials enroling 13, 958 patients with colorectal cancer.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">We compared standard therapies with those therapies plus cetuximab or panitumumab.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">We assessed risk of severe diarrhea and mucositis in intervention and control groups.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">We found an increased risk in patients receiving Cetuximab or panitumumab.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Adopting risk reduction strategies to limit impact of these AEs is needed.</p> </list-item> </list> </p> </sec> </abstract>